Inspiratory Muscle Training in Chronic Obstructive Pulmonary Disease
Launched by FACULDADE EVANGELICA DO PARANA · Jan 25, 2010
Trial Information
Current as of September 14, 2025
Completed
Keywords
ClinConnect Summary
Study design: A double-blind parallel controlled trial Setting: outpatient clinic Inclusion criteria: Subjects between 40 and 75 years of age referred by a physician to the Pulmonary Rehabilitation Program, with a clinical and spirometric diagnosis of moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Outcome measurements: Inspiratory muscle strength (using maximal inspiratory pressure, MIP), exercise capacity (using six-minute walk test) and dyspnea were measured.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with a clinical and spirometric diagnosis of moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
- • In a stable condition (without exacerbations or infections for at least a month)
- • Had to be former smokers (\> 6 months without smoking)
- • subjects referred by a physician to the Pulmonary Rehabilitation Program
- Exclusion Criteria:
- • Subjects with a known history of asthma, or severe and/or unstable heart disease or any other pathological condition that could impair their physical activities
About Faculdade Evangelica Do Parana
Faculdade Evangélica do Paraná is a distinguished educational and research institution located in Brazil, dedicated to advancing healthcare through innovative clinical research and training. With a strong emphasis on ethical standards and scientific rigor, the institution conducts clinical trials aimed at enhancing medical knowledge and improving patient outcomes. By fostering collaboration among healthcare professionals, researchers, and academic partners, Faculdade Evangélica do Paraná strives to contribute significantly to the fields of medicine and public health, ensuring that its research initiatives are aligned with the needs of the community and the broader healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Silvia R Valderramas, PhD
Study Chair
Evangelical Faculty of Paraná
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials